Self-Expanding Peripheral Stent Study Enrollment Completed

 

August 9, 2010

August 9, 2010 – Enrollment was recently completed in a clinical trial of Medtronic’s Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA).

Approved by the U.S. Food and Drug Administration (FDA) under an investigational device exemption (IDE), the Complete SE SFA study is a prospective, multicenter, single-arm trial to evaluate the safety and efficacy of the Complete SE vascular stent system in the treatment of de novo and/or restenotic lesions or occlusions in the SFA/PPA. The study enrolled 196 patients with symptomatic, ischemic PAD. The primary endpoints are major adverse events (MAEs) and patency of the stent at 12 months.

PAD of the lower extremities, including the SFA, affects approximately 8 million people in the United States each year, although many patients are unaware of their condition or its consequences. PAD patients have a two- to six-fold increase in cardiovascular mortality and a significantly increased risk of amputation, disability and diminished quality of life.

“Many people are unable to recognize the symptoms of PAD, and the condition is often undiagnosed by healthcare professionals,” said John Laird, M.D., medical director of the Vascular Center at the University of California (UC), Davis, who served as the study’s U.S. principal investigator. “With this trial, Medtronic is partnering with physicians around the world to expand clinical knowledge about a potentially serious health condition while at the same time generating data in support of the safety and efficacy of its Complete SE stent in the treatment of PAD.”

For more information: www.medtronic.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.